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East Africa has a high tuberculosis (TB) incidence andmortality, yet there are very limited data on exposure to TB drugs in pa-
tients from this region.We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian pa-
tients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before
and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h
(AUC0–24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status
for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid meta-
bolic ratio at 3 h postdose. The geometric mean AUC0–24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h ·
mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for iso-
niazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and
ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping
results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the refer-
ence range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common
practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with
worse treatment outcome in several other studies.
The pharmacokinetic properties of tuberculosis (TB) drugs arewell described, especially in Caucasian populations (1, 2).
Pharmacokinetic data from East Africa are limited, especially data
that are based on intensive pharmacokinetic sampling during the
full dosing interval. Such intensive pharmacokinetic sampling en-
ables an accurate assessment of the total exposure to TB drugs
(area under the time-versus-plasma concentration curve from 0
to 24 h [AUC0 –24]) and the peak plasma concentration (Cmax) in
individual patients. Large interpatient variability in these key
pharmacokinetic parameters of TB drugs generally exists (1). As a
result, a proportion of patients achieve drug concentrations that
are below the reference range for TB drugs. Several studies have
shown that such lower exposures to TB drugs are associated with a
suboptimal response (3–8) A recent study showed that pharma-
cokinetic variability to just a single drug in the multidrug TB drug
regimen is associated with treatment failure and acquired drug
resistance (9, 10).
On the other hand, unduly high exposures may cause toxicity
and interruption of TB treatment. It is therefore important to have
more knowledge on the pharmacokinetic properties of TB treat-
ment in populations from East Africa, as a high TB incidence and
a high TB mortality are found in this region (11). HIV infection
(12–14) and malnutrition (15) have been associated with de-
creased plasma concentrations of TB drugs. Both are highly prev-
alent among East African TB patients, and therefore, low TB drug
levels are to be expected in this population (11).
The objective of this study was to describe the pharmacokinetic
parameters of isoniazid, rifampin, pyrazinamide, and ethambutol
using intensive sampling during the full dosing interval in Tanza-
nian TB patients.
MATERIALS AND METHODS
Study design. We conducted an observational pharmacokinetic study at
the Kilimanjaro Clinical Research Institute at the Kilimanjaro Christian
Medical Centre (KCMC) in Moshi, Tanzania, using the standard two-
stage approach. With this approach, individual pharmacokinetic param-
eters are estimated in the first stage. In the second stage, population char-
acteristics of each parameter are derived by obtaining measures of central
tendency and spread of all the subjects’ individual parameters.
Study participants. Study participants were recruited from an outpa-
tient tuberculosis treatment clinic at Mawenzi Hospital in Moshi. Adult
TB patients who were in the intensive phase of treatment and who were
not using medication that could interfere with TB drug plasma concen-
trations were eligible for participation. All participants gave written in-
formed consent. The study was approved by the local Institutional Re-
search Board at KCMC and by the Tanzanian National Institute of
Medical Research.
Tuberculosis was treated with fixed-dose combination tablets (FDC
tablets) that were manufactured by Sandoz, Mumbai, India, and are on
the WHO list of prequalified medicinal products. The drugs were donated
by Novartis through the WHO Global Drug Facility (GDF), which pro-
vides only high-quality drugs that meet stringent WHO standards. Pa-
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tients with a body weight of less than 50 kg use three FDC tablets per day
(i.e., 225 mg isoniazid, 450 mg rifampin, 1,200 mg pyrazinamide, and 875
mg ethambutol), and patients with a body weight of50 kg use four FDC
tablets per day (i.e., 300 mg isoniazid, 600 mg rifampin, 1,600 mg pyrazi-
namide, and 1,100 mg ethambutol) (16).
Data collection. Basic demographic and clinical information was col-
lected from all participants, including age, sex, body weight and height (to
calculate body mass index [BMI]), comorbidities (including HIV infec-
tion and hepatitis B and C), and concomitant drug use. Malnutrition was
defined as a BMI of18.5 kg/m2 (17).
Sample collection. Pharmacokinetic sampling took place at KCMC
hospital. Patients had to be on TB treatment for at least 10 days because of
the expected steady state in the pharmacokinetics of the TB drugs at that
point. Patients had refrained from food consumption for at least 8 h
before drug intake. On the sampling day, patients took their drugs under
our supervision at 8 a.m. They then had a standardized breakfast within 30
min after drug intake, which reflected the usual drug intake procedures in
this population. The standardized breakfast consisted of a cup (125 ml) of
tea with whole milk and sugar and either a small bowl of porridge or
mandaazi, a typical East African fried pastry (analogous to a doughnut)
that is rather high in fat.
Serial venous blood samples were collected just before, and at 1, 2, 3, 4,
6, 8, 10, and 24 h after observed TB drug intake. Plasma was separated and
stored at 80°C immediately until transport on dry ice to The Nether-
lands for bioanalysis.
Bioanalysis. The plasma concentrations of isoniazid, rifampin, pyr-
azinamide, and ethambutol were assessed by validated high-performance
liquid chromatography (HPLC) as described before (18). Isoniazid and
acetylisoniazid (acetyl-INH) were measured with liquid-liquid extraction
followed by ultra-performance liquid chromatography (UPLC) with UV
detection. Accuracy was between 97.8% and 106.7% for isoniazid and
between 98.0% and 108.9% for acetylisoniazid, depending on the concen-
tration level. The intra- and interassay coefficients of variation were less
than 13.4% and less than 3.2% (depending on the concentration), respec-
tively, over the range of 0.05 to 15.1 mg/liter for isoniazid and less than
4.2% and less than 5.7%, respectively, over the range of 0.16 to 16.2 mg/
liter for acetylisoniazid. Lower limits of quantification were 0.05 mg/liter
for isoniazid and 0.16 mg/liter for acetylisoniazid. Isoniazid- and acetyli-
soniazid-containing samples were stable (5% loss) for at least 12
months at80°C.
Pharmacokinetic analysis. Pharmacokinetic evaluations were per-
formed using noncompartmental methods in WinNonLin version 5.3
(Pharsight Corp., Mountain View, CA). The highest observed plasma
concentration was defined as the Cmax and the corresponding sampling
time as the time to Cmax (Tmax). The log-linear period (log C versus t) was
based on the last data points (at least three). The absolute value of the
slope (/2.303, in which is the first-order elimination rate constant) was
calculated using linear regression analysis. The elimination half-life (T1/2)
was calculated as 0.693/. If the concentration at 24 h (C24) was below the
limit of quantification of the assay (which was often the case for isoniazid
and rifampin), it was estimated based on the last measurable concentra-
tion (Clast) andusing the formulaC24Clast · e
[ · (24 T last)]. The area
under the plasma concentration-time curve from 0 to 24 h (AUC0 –24) was
calculated using the linear/log-trapezoidal rule from zero up to the last
concentration at 24 h. The apparent clearance of the drug (CL/F, where F
is bioavailability) was calculated as dose/AUC0 –24, and the apparent vol-
ume of distribution (V/F) was calculated as (CL/F)/. The reference
ranges for Cmax were 3 to 5 mg/liter for isoniazid, 8 to 24 mg/liter for
rifampin, 20 to 50 mg/liter for pyrazinamide, and 2 to 6 mg/liter for
ethambutol (19).
These reference ranges represent the normal Cmaxs that can be ex-
pected in adults after the standard doses of anti-TB drugs. They are based
on data that were compiled from all available sources (for both healthy
volunteers and TB patients) by, among others, Holdiness (1) and Pelo-
quin (2). Subsequently, the ranges were validated in a range of phase I
studies in healthy volunteers (C. A. Peloquin, presented at the 51st Inter-
sci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 Septem-
ber 2011).
Determination of acetylator status. We determined the acetylator
status phenotypically by assessing the t1/2 of isoniazid. Participants with a
t1/2 of greater than 130 min were classified as slow metabolizers, and those
with a t1/2 of less than 130 min were classified as fast/intermediate metabo-
lizers (21–23). As another means to assess acetylator phenotype, the met-
abolic ratio of acetylisoniazid concentration to isoniazid concentration at
3 h postdose was calculated. Patients with a ratio above 1.5 were consid-
ered fast/intermediate metabolizers, and patients with a ratio below 1.5
were considered slow metabolizers (21). In addition, we also explored a
metabolic ratio of 0.55 at 3 h postdose as a cutoff to distinguish fast/
intermediate from slow metabolizers, as this evolved from a study in Af-
rican patients (23).
Statistical analysis. Most pharmacokinetic parameters were pre-
sented as geometric means. The sample size was considered too small to
test for associations between patient characteristics and pharmacokinetic
parameters. We tested the effect of acetylator status only on the pharma-
cokinetics of isoniazid. The correlations between the Cmax and AUC0 –24
of each of the drugs were explored using Spearman’s rho correlation.
To explore the potential of limited sampling for estimating the
AUC0 –24 based on sampling early in the pharmacokinetic curve, univar-
iate linear regression was used to determine the association between the
plasma concentration at 2, 3, 4, and 6 h postdose and the AUC0 –24 for each
of the drugs. The r2 value was presented as a measure of variance in the
AUC0 –24 that is explained by the variance in the concentration at that time
point. Statistical analyses were performed in STATA version 10.1 (Stata
Corp. LP, College Station, TX).
RESULTS
Twenty tuberculosis patients were enrolled for this study. All were
under community-based directly observed treatment. Their median
age was 38 years (interquartile range [IQR], 30 to 42 years), 15 pa-
tients (75%) were male, seven (35%) were HIV positive, and seven
(35%) were considered malnourished based on their BMI (Table 1).
Descriptive pharmacokinetics. Intensive pharmacokinetic
sampling took place after a median of 19 days after the start of TB
treatment (range, 11 to 49 days). The pharmacokinetic parameters
for isoniazid, rifampin, pyrazinamide, and ethambutol are presented
in Table 2. In 10 patients (53%), the isoniazid peak plasma concen-
tration was below the reference range (3 to 5 mg/liter). In seven pa-
tients (35%), the rifampinCmax was below the reference range (8 to 24
mg/liter); in five of them, the isoniazid Cmax was also below the ref-
erence range. In none of the patients was theCmax of pyrazinamide or
ethambutol below the reference range.
There was a positive correlation between the AUC0 –24 and
Cmax of isoniazid (correlation coefficient, 0.68; P  0.001), pyr-
azinamide (correlation coefficient, 0.69; P  0.001), and etham-
butol (correlation coefficient 0.72; P  0.003) but not between
those of rifampin (correlation coefficient, 0.35; P 0.14).
Assessment of acetylator status. Based on the elimination
half-life of isoniazid, 7 (37%) patients were fast or intermediate
metabolizers and 12 (63%) were slow metabolizers. Based on the
3-hour acetyl-INH/INH ratio with a cutoff of 1.5, nine patients
(47%) were fast/intermediate metabolizers and 10 patients (53%)
were slow metabolizers (Fig. 1). Two patients had a discrepancy in
acetylator phenotype determined by the two methods. With a cut-
off of 0.55, 11 patients (58%) were fast/intermediate metabolizers
and eight (42%) were slow metabolizers.
Acetylator status based on the half-life method was associated
with the AUC0 –24 and Cmax of isoniazid. In slow metabolizers, the
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July 2013 Volume 57 Number 7 aac.asm.org 3209
geometric mean AUC0 –24 was 17.2 h · mg/liter (range, 9.5 to 22.7)
and the Cmax was 3.4 mg/liter (range, 2.0 to 4.6), and in interme-
diate/fast metabolizers, the geometric mean AUC0 –24 was 5.2 h ·
mg/liter (range 3.7 to 8.1) and theCmax was 2.0 mg/liter (range, 1.0
to 3.3) (P 0.001 and P 0.01, respectively).
Association between the 2-, 3-, 4-, and 6-h concentrations
and AUC0–24. The isoniazid concentrations at 2, 3, 4, and 6 h
postdose were associated with AUC0 –24, and the r
2 value ranged
from 0.91 to 0.96, meaning that 91 to 96% of the variance in the
AUC0 –24 is explained by the variance in the concentration at a
particular sampling time point. For rifampin, the r2 value was
highest for the concentration at 4 h postdose (0.82). For pyrazin-
amide, the r2 value was highest for the concentrations at 4 and 6 h
postdose (0.84 and 0.86, respectively). For the different ethambu-
tol concentrations, the r2 value was low, varying from 0.40 to 0.71.
This indicates that limited sampling to estimate the AUC0 –24 may
be feasible for isoniazid, rifampin, and pyrazinamide but less for
ethambutol.
DISCUSSION
This report provides important data on the pharmacokinetic
characteristics of isoniazid, rifampin, pyrazinamide, and etham-
butol based on intensive 24-hour pharmacokinetic sampling in
East African TB patients.
Half of the patients from our study had an isoniazid peak
plasma concentration (Cmax) below the reference range, and a
third of patients had a rifampin Cmax below the reference range.
This may partly be explained by the breakfast that patients took
within half an hour after the intake of TB drugs. This approach
was chosen to mimic the real-life situation for TB patients, as most
TB patients take their pills just before or with their breakfast in
order to prevent or alleviate gastrointestinal adverse effects. Pre-
vious studies have shown that intake of a meal with a high fat or
carbohydrate content just before drug intake decreases the rate of
absorption and significantly reduces the isoniazid Cmax by 20% to
51% (24–27). The rifampin Cmax can be reduced up to 36% when
it is taken directly after a meal (24, 28). There is no significant
effect of food on the Cmaxs of pyrazinamide and ethambutol (24,
29, 30). Of note, in the current study the average Tmax values for
the TB drugs were short (about 1 h for isoniazid, rifampin, and
pyrazinamide) (Table 2), indicating that the delay in absorption
and a possible related decrease in Cmax were probably limited.
Furthermore, it should be noted that pharmacokinetic studies
from other African countries found even higher proportions of
patients with Cmaxs below the reference range for isoniazid (30%
in Botswana [8, 31] and 89% in Kenya [32]) and rifampin (69% in
South Africa [12], 78 to 84% in Botswana [27, 28], and 90% in
Kenya [32]), despite administration of drugs on an empty stom-
ach in the studies from Botswana and Kenya. The relatively high
Cmaxs of the TB drugs in our study among African patients may
also relate to the average body weight of 55.7 kg (Table 1), which is
TABLE 1 Characteristics of 20 tuberculosis patients in northern
Tanzania
Characteristic Value
Male sex, n (%) 15 (75)
Age, median, yr (IQR) 38 (30–42)
Body wt, mean, kg (SD) 55.7 (6.4)
BMI, mean (SD) 19.5 (2.4)
Malnutrition, n (%)a 7 (35)
HIV positive, n (%) 7 (35)
Type of tuberculosis, n (%)
Pulmonary 19 (95)
Extrapulmonary 1 (5)
Concomitant drugs, n (%)
Amoxicillin 1 (5)
Antiretroviral treatment 2 (10)
Co-trimoxazole 3 (15)
Diclofenac 3 (15)
Vitamin B complex 2 (10)
Dose, mean, mg per kg body wt (SD)
Isoniazid 5.2 (0.46)
Rifampin 10.4 (0.91)
Pyrazinamide 27.8 (2.4)
Ethambutol 19.1 (1.7)
Acetylator status, n (%,) based on:
INH t1/2
Slow 12 (63)
Fast/intermediate 7 (37)
Acetyl-INH/INH ratio with cutoff of:
1.5
Slow 10 (53)
Fast/intermediate 9 (47)
0.55
Slow 8 (42)
Fast/intermediate 11 (58)
a Malnutrition defined as BMI of18.5 kg/m2.
TABLE 2 Pharmacokinetic parameters of tuberculosis drugs in 20 Tanzanian tuberculosis patients
Pharmacokinetic parameter
Value, geometric mean (minimum-maximum) for:
Isoniazida Rifampin Pyrazinamide Ethambutol
AUC0–24, h · mg/liter 11 (3.7–22.7) 39.9 (27.4–68.3) 344 (209–610) 20.2 (13.4–32.0)
Cmax, mg/liter 2.8 (1.0–4.6) 8.9 (5.9–14.8) 38.2 (29.0–50.8) 3.3 (2.2–5.8)
Tmax, h 1.2 (0.7–2.9) 1.3 (0.9–3.0) 1.2 (0.7–3.0) 1.5 (0.9–2.2)
CL/F, liters/h 25.8 (13.0–60.5) 14.4 (8.8–21.9) 4.5 (2.6–6.5) 52 (34.3–71.3)
V/F, liters 99 (69.6–173.4) 37.3 (22.7–56.5) 40.3 (29.5–98.3) 719 (491–965)
t1/2, h 2.9 (1.3–4.2) 1.8 (1.1–3.8) 5.5 (4.1–15.7) 9.5 (6.9–13.5)
Reference range Cmax, mg/liter 3–5 8–24 20–50 2–6
No. (%) with Cmax below reference range 10 (52) 7 (35) 0 (0) 0 (0)
a Isoniazid plasma concentrations were determined for only 19 patients.
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just above 50 kg, above which 4 FDC tablets (rather than 3) are
administered.
Values for total exposure (AUC0 –24) may be even more rele-
vant to the efficacy of first-line TB drugs than the Cmax (33).
AUC0 –24 values can best be compared to those recorded in Indo-
nesian TB patients (18) and in a racially mixed population of
patients in The Netherlands who used similar doses on a mg/kg
basis (C. Magis-Escurra, H. M. J. Later-Nijland, J. W. C. Alffenaar,
J. Broeders, D. M. Burger, R. van Crevel, M. J. Boeree, A. R. T.
Donders, R. van Altena, T. S. van der Werf, and R. E. Aarnoutse,
submitted for publication), as the pharmacokinetics in these stud-
ies were assessed with the same analytical methodology. Average
exposures to rifampin were 39.9, 48.5, and 41.1 h · mg/liter in the
Tanzanian patients, the Indonesian patients, and a mixed popu-
lation, pyrazinamide AUC0-24 values were 344, 473, and 380 h ·
mg/liter, respectively, and exposures to ethambutol were 20.2,
14.4, and 23.5 h · mg/liter, respectively. Isoniazid was not mea-
sured in the Indonesian TB patients, and we used another analyt-
ical method with the mixed population (the average AUC0-24 was
15.2 h · mg/liter, compared to 11.0 in the current study). These
comparisons show no drastically lower total exposure to TB drugs
between Tanzanian patients and the Indonesian patients and the
mixed population from the Netherlands.
Even though the exposure to TB drugs in Tanzanian patients
may be high compared to exposure in other African studies and
similar to those in other populations, a large number of patients
had low plasma concentrations of isoniazid and rifampin., Several
clinical studies have pointed toward a possible association be-
tween low TB drug concentrations and poor treatment outcome
(3–5). A preclinical model showed that interindividual variability
in pharmacokinetics is relevant to the emergence of resistance (7),
and a recent meta-analysis revealed that variability in exposure to
isoniazid is associated with failure of therapy and acquired drug
resistance (10). On the other hand, other studies have found no
association between plasma concentrations and effect of first-line
TB drugs (34, 35).
We could not readily explain the observed low isoniazid and
rifampin AUC0-24s and Cmaxs by patient characteristics, as the
sample size was considered too small for analysis of association
between patient characteristics and pharmacokinetic parameters.
However, we evaluated the effect of genetic polymorphisms in
N-acetyltransferase 2 (NAT2), a phase II metabolic enzyme, on
the pharmacokinetics of isoniazid. Slow acetylation of isoniazid
into acetylisoniazid is a homozygous recessive trait. Genotypi-
cally, homozygous fast, heterozygous fast (or intermediate), and
slow acetylators are distinguished (22, 36). In our study, acetylator
status was assessed phenotypically using the isoniazid elimination
half-life and the acetylisoniazid/isoniazid ratio at 3 h postdose
with a cutoff of 1.5. Based on these two methods, 63% or 53% of
patients in our study, respectively, were slow metabolizers. This is
consistent with available data showing that 50 to 60% of European
(Caucasian), African, and Indian populations are slow metaboliz-
ers (37). Clearly, assessment of the acetylator status by the acetyli-
soniazid/isoniazid metabolic ratio at a single time point postdose
FIG 1 Relationship between the acetylator status (slow versus fast/intermediate) based on two methods: the t1/2 of isoniazid and the acetyl-INH/INH metabolic
ratio in the 3-h-postdose plasma sample. Patients with a t1/2 below 130 min (below the horizontal dashed line) were considered fast/intermediate metabolizers
(17–19). Patients with an acetyl-INH/INH ratio greater than 0.55 (19) or greater than 1.5 (17) (right of the first or second vertical dashed line, respectively) were
considered fast/intermediate metabolizers based on metabolic ratio. Note that phenotyping by t1/2 and metabolic ratio resulted in discordant results (in the upper
right quadrant) in 4 patients when a metabolic ratio of 0.55 was used as the cutoff, compared to 2 patients when a metabolic ratio of 1.5 was used as the cutoff.
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is more convenient. There was good concordance between the two
methods when 1.5 was used as the cutoff for the metabolic ratio
(there were 2 discordant patients). In the future, limited sampling
may allow for an assessment of acetylator status as well as estima-
tion of AUC values of TB drugs, considering the high correlation
between concentrations measured in the early part of the pharma-
cokinetic curve and exposures to isoniazid, rifampin, and pyrazi-
namide. The AUC0-24s and Cmaxs of isoniazid, pyrazinamide, and
ethambutol were also correlated, but for rifampin no such associ-
ation was found. We have considered whether this may be ex-
plained by the nonlinear, saturable pharmacokinetics of rifampin,
but disproportional changes in exposure above certain concentra-
tions are expected to affect both Cmax and AUC0-24.
In summary, this study provides pharmacokinetic data for
first-line TB drugs based on intensive 24-h sampling in East Afri-
can TB patients. Half of the patients had isoniazid peak plasma
levels and a third had rifampin peak plasma concentrations below
the reference ranges. Although the pharmacodynamics of the cur-
rently used first-line TB drugs are not entirely clear, low isoniazid
and rifampin concentrations have been associated with a subop-
timal treatment response. Exploring the effect, tolerability, and
pharmacokinetics of higher doses of isoniazid and rifampin in
African tuberculosis patients is therefore recommended.
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